{"id":7018,"date":"2026-05-18T11:00:00","date_gmt":"2026-05-18T09:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=bee374dda05e4364e826c2b15a957424"},"modified":"2026-05-18T11:00:00","modified_gmt":"2026-05-18T09:00:00","slug":"abl-diagnostics-proposes-a-significant-increase-in-its-dividend-for-fy2025","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=7018","title":{"rendered":"ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025"},"content":{"rendered":"

\nProposed dividend of \u20ac0.11 per share, up +120%, reflecting the Company\u2019s improved financial performance and solid financial position<\/i><\/p>

WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p>

\nABL Diagnostics (Euronext Paris \u2013 FR001400AHX6), a company specialized in molecular diagnostics for infectious diseases, announces that its Board of Directors, at its meeting held on April 30, 2026, has decided to propose to the Combined General Meeting to be held on June 30, 2026 the distribution of a dividend of \u20ac0.11 per share for the financial year ended December 31, 2025.<\/p>

\nThis proposal, which remains subject to shareholders\u2019 approval, is in line with the Company\u2019s dividend policy, following the first dividend paid in respect of FY2024 in the amount of \u20ac0.05 per share. It reflects ABL Diagnostics\u2019 intention to establish a sustainable shareholder return, consistent with its development and financial position.<\/p>

\nThe proposed dividend amounts to approximately \u20ac1.77 million in aggregate and would, if approved, be detached on July 3, 2026, with payment scheduled for July 7, 2026, entirely in cash.<\/p>

\nThis proposal comes in a context of significant improvement in the Company\u2019s financial performance for FY2025. ABL Diagnostics reported revenue of \u20ac6.95 million, representing an increase of over 30% compared to the previous year, as well as net profit close to \u20ac1.0 million, reflecting strong growth. This performance was accompanied by a significant improvement in operating profitability and strengthened cash generation, allowing for a marked reduction in net debt.<\/p>

\nIn this context, the proposed dividend distribution reflects ABL Diagnostics\u2019 ability to combine business growth, improved profitability and financial discipline. It also illustrates a balanced approach between funding the investments required to support the Company\u2019s development and sharing value creation with its shareholders.<\/p>

\nABL Diagnostics continues to implement its strategy focused on expanding its molecular diagnostics solutions portfolio, strengthening its international footprint and progressively deploying new integrated activities. In a sector where growth-stage diagnostic companies typically prioritize reinvestment, the Company\u2019s ability to propose an increasing dividend reflects the growing maturity of its business model.<\/p>

\nABL Diagnostics\u2019 dividend policy may evolve over time depending on its results, financial position, investment needs and development opportunities.<\/p>

\nThis press release contains forward-looking statements based on the Company\u2019s current expectations. These statements involve risks and uncertainties that may cause actual results to differ materially. The payment of the dividend remains subject to approval by the General Meeting of shareholders.<\/p>

\nAbout ABL Diagnostics (ABLD)<\/b><\/p>

\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p>